1-9 of 9
Andrew M. Waters
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract B068: Human pancreatic cancer single cell atlas reveals association of CXCL10 positive fibroblasts and basal subtype tumor cells

Ian M Loveless, Samantha B Kempt, Yuesong Wu, Daniel J Salas-Escabillas, Kailee Hartway, Madison George, Yetunde Makinwa, Thais Stockdale, Samuel D Zwernik, Kendyll Gartrelle, Rohit G Reddy, Daniel Long, Allison Wombell, Julie M Clark, Albert M Levin, David Kwon, Ling Huang, Ralph Francescone, Débora B Vendramini-Costa, Ben Stanger, Adam Alessio, Andrew M Waters, Yuehua Cui, Brian Theisen, Howard C Crawford, Nina G Steele
Journal: Cancer Research
Cancer Res (2024) 84 (17_Supplement_2): B068.
https://doi.org/10.1158/1538-7445.PANCREATIC24-B068
Published: 15 September 2024
View article titled, Abstract B068: Human pancreatic cancer single cell atlas reveals association of CXCL10 positive fibroblasts and basal subtype tumor cells
Journal Articles

Abstract PR-16: Evaluating direct KRASQ61H inhibition in pancreatic cancer models

Szu-Aun Long, Amber M Amparo, Haley Todd, Grace Goodhart, Syed A Ahmad, Andrew M Waters
Journal: Cancer Research
Cancer Res (2024) 84 (17_Supplement_2): PR-16.
https://doi.org/10.1158/1538-7445.PANCREATIC24-PR-16
Published: 15 September 2024
View article titled, Abstract PR-16: Evaluating direct KRAS<sup>Q61H</sup> inhibition in pancreatic cancer models
Journal Articles

Abstract 1936: KEAP1-NRF2 mediated resistance against KRASG12D inhibitor in pancreatic ductal adenocarcinoma

Wen-Hsuan Chang, Addison G. Stamey, Andrew M. Waters, Kirsten L. Bryant, Adrienne D. Cox, Channing J. Der
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 1936.
https://doi.org/10.1158/1538-7445.AM2024-1936
Published: 22 March 2024
View article titled, Abstract 1936: KEAP1-NRF2 mediated resistance against KRAS<sup>G12D</sup> inhibitor in pancreatic ductal adenocarcinoma
Journal Articles

Abstract 4588: Combination of MTA-cooperative PRMT5 inhibitor and direct mutant-selective KRAS inhibitors as a novel therapeutic approach for MTAP-deficient pancreatic cancer

Kristina Drizyte-Miller, Wen-Hsuan Chang, Andrew M. Waters, Clint A. Stalnecker, Junning Wang, Andrew J. Aguirre, Adrienne D. Cox, Channing J. Der
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 4588.
https://doi.org/10.1158/1538-7445.AM2024-4588
Published: 22 March 2024
View article titled, Abstract 4588: Combination of MTA-cooperative PRMT5 inhibitor and direct mutant-selective KRAS inhibitors as a novel therapeutic approach for MTAP-deficient pancreatic cancer
Journal Articles

TEAD Inhibition Overcomes YAP1/TAZ-Driven Primary and Acquired Resistance to KRASG12C Inhibitors

A. Cole Edwards, Clint A. Stalnecker, Alexis Jean Morales, Khalilah E. Taylor, Jennifer E. Klomp, Jeffrey A. Klomp, Andrew M. Waters, Niranjan Sudhakar, Jill Hallin, Tracy T. Tang, Peter Olson, Leonard Post, James G. Christensen, Adrienne D. Cox, Channing J. Der
Journal: Cancer Research
Cancer Res (2023) 83 (24): 4112–4129.
https://doi.org/10.1158/0008-5472.CAN-23-2994
Published: 15 December 2023
View article titled, TEAD Inhibition Overcomes YAP1/TAZ-Driven Primary and Acquired Resistance to KRAS<sup>G12C</sup> Inhibitors
Open the PDF for TEAD Inhibition Overcomes YAP1/TAZ-Driven Primary and Acquired Resistance to KRAS<sup>G12C</sup> Inhibitors in another window
Includes: Supplementary data
Journal Articles

Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer

Craig M. Goodwin, Andrew M. Waters, Jennifer E. Klomp, Sehrish Javaid, Kirsten L. Bryant, Clint A. Stalnecker, Kristina Drizyte-Miller, Bjoern Papke, Runying Yang, Amber M. Amparo, Irem Ozkan-Dagliyan, Elisa Baldelli, Valerie Calvert, Mariaelena Pierobon, Jessica A. Sorrentino, Andrew P. Beelen, Natalie Bublitz, Mareen Lüthen, Kris C. Wood, Emanuel F. Petricoin, III, Christine Sers, Autumn J. McRee, Adrienne D. Cox, Channing J. Der
Journal: Cancer Research
Cancer Res (2023) 83 (1): 141–157.
https://doi.org/10.1158/0008-5472.CAN-22-0391
Published: 04 January 2023
View article titled, Combination Therapies with CDK4/6 Inhibitors to Treat <em>KRAS-</em>Mutant Pancreatic Cancer
Open the PDF for Combination Therapies with CDK4/6 Inhibitors to Treat <em>KRAS-</em>Mutant Pancreatic Cancer in another window
Includes: Supplementary data
Journal Articles

Aberrant Expression and Subcellular Localization of ECT2 Drives Colorectal Cancer Progression and Growth

Danielle R. Cook, Melissa Kang, Timothy D. Martin, Joseph A. Galanko, Gabriela H. Loeza, Dimitri G. Trembath, Verline Justilien, Karen A. Pickering, David F. Vincent, Armin Jarosch, Philipp Jurmeister, Andrew M. Waters, Priya S. Hibshman, Andrew D. Campbell, Catriona A. Ford, Temitope O. Keku, Jen Jen Yeh, Michael S. Lee, Adrienne D. Cox, Alan P. Fields, Robert S. Sandler, Owen J. Sansom, Christine Sers, Antje Schaefer, Channing J. Der
Journal: Cancer Research
Cancer Res (2022) 82 (1): 90–104.
https://doi.org/10.1158/0008-5472.CAN-20-4218
Published: 04 January 2022
View article titled, Aberrant Expression and Subcellular Localization of ECT2 Drives Colorectal Cancer Progression and Growth
Open the PDF for Aberrant Expression and Subcellular Localization of ECT2 Drives Colorectal Cancer Progression and Growth in another window
Includes: Supplementary data
Journal Articles

Abstract LB-287: Combination therapies with CDK4/6 inhibitors to treat KRAS-mutant pancreatic cancer

Craig M. Goodwin, Sehrish Javaid, Andrew M. Waters, Bjoern Papke, Runying Yang, Mariaelena Pierobon, Daniel M. Freed, Patrick J. Roberts, Adrienne D. Cox, Kris C. Wood, Emanuel F. Petricoin, Autumn J. McRee, Channing J. Der
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): LB-287.
https://doi.org/10.1158/1538-7445.AM2019-LB-287
Published: 01 July 2019
View article titled, Abstract LB-287: Combination therapies with CDK4/6 inhibitors to treat <em>KRAS-</em>mutant pancreatic cancer
Journal Articles

Abstract LB-276: Farnesyltransferase inhibitor (FTI)-induced growth inhibition of HRAS-mutant head and neck cancers is enhanced by concurrently inhibiting compensatory upregulation of the ERK-MAPK kinase cascade

Sehrish Javaid, Victoria V. Nguyen, Andrew M. Waters, Craig M. Goodwin, Channing J. Der, Adrienne D. Cox
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): LB-276.
https://doi.org/10.1158/1538-7445.AM2019-LB-276
Published: 01 July 2019
View article titled, Abstract LB-276: Farnesyltransferase inhibitor (FTI)-induced growth inhibition of HRAS-mutant head and neck cancers is enhanced by concurrently inhibiting compensatory upregulation of the ERK-MAPK kinase cascade